Nateplase

Drug Profile

Nateplase

Alternative Names: Milyzer; MMR 701; Tepase

Latest Information Update: 08 Oct 2007

Price : $50

At a glance

  • Originator Nihon Schering
  • Developer Bayer Yakuhin; Mochida Pharmaceutical
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Myocardial infarction

Most Recent Events

  • 12 Feb 1997 Launched for Myocardial infarction in Japan (IV-injection)
  • 22 Jul 1996 Registered for Myocardial infarction in Japan (IV-injection)
  • 13 Dec 1995 MMR 701 is now called nateplase
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top